Illumina last week said fourth-quarter revenue swelled 43 percent as a loss in the prior-year period swung to a profit in the current quarter, and Chief Financial Officer Christian Henry said it will "probably" make an acquisition that is on the "smaller rather than the larger side."

CEO Jay Flatley said sales of the firm’s whole-genome Infinium HD BeadChips comprised the majority of its revenue, and that its Human610-Quad was its best-selling product for the quarter.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.